Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is rituximab effective as a single agent in mantle-cell lymphoma?

Nature Clinical Practice Oncology volume 2, pages 500–501 (2005)Cite this article

boxed-textGhielmini M et al. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle-cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23: 705–711

Rituximab (induction and/or maintenance) shows clinical activity, synergism with other anti-cancer drugs, and promise in combination therapy trials that will help define its optimal use in MCL

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Grillo-López AJ (2004) The ODAC chronicles: Part II. Statistics and clinical medicine in the USA—the triumph of science over art? Expert Rev Anticancer Ther 4: 941–944

    Article  Google Scholar 

  2. Howard O et al. (2002) Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. J Clin Oncol 20: 1288–1294

    Article  CAS  Google Scholar 

  3. Demidem A et al. (1997) Chimeric antiCD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12: 177–185

    Article  CAS  Google Scholar 

  4. Dreyling MH et al. (2003) Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma—final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood 102 (Suppl): a351

    Google Scholar 

  5. Lenz G et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984–1992

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chairman of the Neoplastic Diseases Research Institute, Rancho Santa Fé, CA, USA

    Antonio J Grillo-López

Authors
  1. Antonio J Grillo-López
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grillo-López, A. Is rituximab effective as a single agent in mantle-cell lymphoma?. Nat Rev Clin Oncol 2, 500–501 (2005). https://doi.org/10.1038/ncponc0297

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0297

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing